Lenalidomide Zentiva

Lenalidomide, the active ingredient in Lenalidomide Zentiva, is an immunomodulatory imide drug (IMiD) presented as a tablet for oral use. It treats multiple myeloma and myelodysplastic syndromes with del(5q) in adult patients, providing anti‑angiogenic and immune‑modulating benefits. GNH USA supplies Lenalidomide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related disorders. - Multiple Myeloma: improves progression‑free survival and overall response rates in relapsed or refractory disease. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and can induce cytogenetic remission. - Mantle Cell Lymphoma: provides therapeutic benefit in patients with relapsed or refractory disease.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels that may cause bruising. - Diarrhea: loose stools that may lead to dehydration. - Rash: mild skin irritation or erythema. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: profound immune suppression requiring medical intervention. - Severe thrombocytopenia: significant bleeding risk. - Secondary primary malignancies: emergence of new cancers. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: life‑threatening skin reactions. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Before initiating therapy, clinicians should evaluate several safety considerations. - Pregnancy: contraindicated; ensure effective contraception due to teratogenic risk. - Thrombosis risk: assess patient history and consider prophylactic anticoagulation. - Hematologic monitoring: perform regular complete blood counts to detect neutropenia or thrombocytopenia. - Renal impairment: adjust dosing and monitor renal function closely. - Drug interactions: avoid concomitant use with strong CYP inducers without supervision. - Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Lenalidomide can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding events. - Immunosuppressants (e.g., cyclosporine): may heighten toxicity.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., verapamil): may raise plasma concentrations. - CYP3A4 inhibitors (e.g., ketoconazole): can increase drug exposure. - Live attenuated vaccines: reduced efficacy; consider timing relative to therapy.